Drugs / Suvemcitug
Suvemcitug
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03763123 | Apr 2018 → Dec 2019 | ovarian cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02453464 | Aug 2015 → Dec 2016 | colorectal cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01847118 | Apr 2013 → Nov 2015 | cancer, metastatic neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05148195 | Dec 2021 → Jul 2023 | neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07361003 | Nov 2025 → Jan 2028 expected | colorectal cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04908787 | Jun 2021 → Dec 2023 | ovarian cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suvemcitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07361003 ↗ |
| Known as | APX 003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315039 ↗ |
| Known as | BD0801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05148195 ↗ |
| Known as | Sevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03763123 ↗ |
| Action | Inhibit | “humanized anti-VEGF monoclonal antibody (Sevacizumab)” NCT01847118 ↗ |
| Modality | Monoclonal antibody | “humanized anti-VEGF monoclonal antibody (Sevacizumab)” NCT01847118 ↗ |